Deborah Schrag | |
---|---|
Nationality | American |
Citizenship | American |
Spouse | Yochai Benkler [1] |
Scientific career | |
Institutions |
Deborah Schrag is the Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center. She currently holds the George H. Bosl Chair. She is a medical oncologist known for her work in patient care and examination of patient outcomes.
Schrag received her undergraduate degree from Harvard University where she studied the history of science. She has an M.D. from Columbia University Medical School and an M.P.H. from Harvard University's School of Public Health. She has worked at Memorial Sloan Kettering Cancer Center and the Dana–Farber Cancer Institute. In 2021 she was named chair of the department of medicine at Memorial Sloan Kettering, [2] and as of 2024 she is the George H. Bosl Chair at Memorial Sloan Kettering Cancer Center. [3]
Schrag is noted for her work in comparing the efficacy of treatments for different forms of cancer. She has examined how the timing of surgery impacts patient outcomes for women with a mutation in a BRCA gene. [4] [5] She led a research trial that examined the necessity of radiation therapy for rectal cancer patients. [6] [7]
Memorial Sloan Kettering Cancer Center is a cancer treatment and research institution in Manhattan in New York City. MSKCC is one of 72 National Cancer Institute–designated Comprehensive Cancer Centers. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan.
Gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. As specialists, they have extensive training in the diagnosis and treatment of these cancers.
SimBioSys is a technology company deploying a combination of artificial intelligence and biophysical simulations to improve the personalized and patient-specific understanding of cancer.
David B. Agus is an American physician, cancer researcher and author who serves as a professor of medicine and engineering at the University of Southern California Keck School of Medicine and Viterbi School of Engineering and the Founding Director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. He is also the cofounder of several personalized medicine companies and a contributor to CBS News on health topics. He is also the author of four books.
Simon N. Powell is a British cancer researcher and radiation oncologist residing in New York City.
George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a professor of medicine at the Weill Cornell Medical College. In 1997, he was appointed chair of the Department of Medicine at Sloan-Kettering, a position which he held until 2015. In 2019, he was named Memorial Sloan Kettering's first ombudsperson.
Peter B. Bach is a physician and writer in New York City. He is the Chief Medical Officer of DELFI Diagnostics and was previously an attending and researcher at Memorial Sloan-Kettering Cancer Center where he was the Director of the Center for Health Policy and Outcomes. His research focuses on healthcare policy, particularly as it relates to Medicare, racial disparities in cancer care quality, and lung cancer. Along with his scientific writings he is a frequent contributor to The New York Times and other newspapers.
The immune-related response criteria (irRC) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment, where the compound being evaluated is an immuno-oncology drug. Immuno-oncology, part of the broader field of cancer immunotherapy, involves agents which harness the body's own immune system to fight cancer. Traditionally, patient responses to new cancer treatments have been evaluated using two sets of criteria, the WHO criteria and the response evaluation criteria in solid tumors (RECIST). The immune-related response criteria, first published in 2009, arose out of observations that immuno-oncology drugs would fail in clinical trials that measured responses using the WHO or RECIST Criteria, because these criteria could not account for the time gap in many patients between initial treatment and the apparent action of the immune system to reduce the tumor burden.
Viviane Tabar is an American neurosurgeon, the Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center in New York since 2017.
Nancy Y. Lee is a Taiwanese-born American physician and the vice-chair of the Department of Radiation Oncology in Memorial Sloan Kettering's Department of Medicine.
The University of Michigan Rogel Cancer Center is a cancer research and treatment institution based in Ann Arbor, Michigan, United States. The Rogel Cancer Center is affiliated with the University of Michigan and Michigan Medicine.
Tina Young Poussaint is a professor of radiology at the Harvard Medical School and a Neuroradiologist at the Boston Children's Hospital. In 2010 she served as President of the American Society of Pediatric Neuroradiology.
Carol L. Brown is the Nicholls-Biondi Chair for Health Equity at Memorial Sloan Kettering Cancer Center and a professor at Weill Cornell Medical College. She is a surgeon known for her work on gynecological cancers.
Kimmie Ng is a physician at Dana–Farber Cancer Institute who is known for her work on colorectal cancer in young patients.
Beth Ann Overmoyer is an American physician and oncologist. She is Director of the Inflammatory Breast Cancer Program at the Dana–Farber Cancer Institute.
Walter Lawrence Jr. was an American surgical oncologist at Memorial-Sloan-Kettering Cancer Center, Cornell Medical College, and at the Medical College of Virginia. He was a leader in civil rights health equity efforts.
Nancy Keating is an American physician who works at the Brigham and Women's Hospital and is a professor at Harvard Medical School. Her research considers the factors that influence quality care for people suffering from cancer.
Valerie W Rusch, MD, FACS, is an American thoracic surgeon who is currently the Miner Family Chair for Intrathoracic Cancers and Vice Chair for Clinical Research, Department of Surgery, at Memorial Sloan Kettering Cancer Center.
Patrick J. Loehrer is an American oncologist who is Indiana University Distinguished Professor, Joseph W. and Jackie J. Cusick Professor in Oncology, Professor of medicine, Indiana University School of Medicine; Director emeritus, Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
The Immune Oncology Research Institute (IMMONC), established in April 2022 and headquartered in Yerevan, is a non-profit organization focusing on cancer research, treatment, and education. The institute's activities include conducting clinical research and building research capacity, with an emphasis on making cancer therapies accessible, particularly in low- and middle-income countries. IMMONC's role is to contribute to the global effort in cancer care through research and development in oncology.